IHS Chemical Week

Archives :: Chem Ideas

Displaying 361 - 372 of 964 stories.
June 22, 2012
This Week on CW:   Cabot has agreed to buy Norit, a Dutch activated carbon maker, for $1.1 billion. Norit, which is owned by private equity firms Doughty Hanson and Euroland...
June 19, 2012
FDA ISSUES CLOSE OUT LETTER TO AKZONOBEL’S API PLANT IN MEXICO The U.S. Food and Drug Administration (FDA) issued a close-out letter on June 11, to Akzo Nobel Chemicals’...
June 15, 2012
This Week on CW:   Cefic has, once again, downgraded its European chemicals output forecast, with the trade group predicting zero growth for the year.   Sachtleben, the TiO2...
June 12, 2012
Reading two recent articles in Organic Process Research & Development magazine had me wondering about my chemistry and chemical engineering education and practices. They created a...
June 12, 2012
PFIZER TO CUT 177 JOBS AT IRELAND API PLANTS Pfizer plans to cut 177 jobs at the company’s two active pharmaceutical ingredient (API) manufacturing plants at Cork, Ireland. The...
June 8, 2012
This Week on CW:   At ACC’s 2012 annual meeting in Colorado Springs, CO, industry leaders expressed growing concern about declining energy and chemical prices and inventory...
June 6, 2012
FINE CHEMICAL COMPANIES MAINTAIN GROWTH DESPITE CHALLENGES Pharmaceutical fine chemical companies and contract manufacturers are seeing a rise in demand for their products and...
June 5, 2012
Shale gas is becoming an important raw material source for the chemical industry as firms in the U.S. invest in these previously untapped resources. The revolution in the supply of...
June 5, 2012
Topping the headlines, the European Commission has cleared Eastman’s $4.7 billion acquisition of Solutia, as Solutia has scheduled a shareholders’ meeting on June 29 to...
June 1, 2012
This Week on CW:   ExxonMobil Chemical has filed permits to build a 1.5 million m.t./year ethane cracker and two 650,000 m.t./year polyethylene plants in Texas.   H.B. Fuller...
May 29, 2012
SENATE APPROVES FDA SAFETY AND INNOVATION ACT The U.S. Senate, on May 24, 2012, approved the Food and Drug Administration Safety and Innovation Act (S. 2516), which would enable the...
May 24, 2012
Quality by Design, or QbD, is targeted at having a robust and repeatable process which produces quality product without rework or re-testing) is financially important for the pharmaceutical industry and highly beneficial for the consumers; as it will ensure quality all the time, and potentially alleviate shortages and lower costs. In order for QbD to become part of the pharma landscape C and E levels of the companies need to have a very clear understanding of cost of regulatory compliance and financial benefits of QbD. Even with the understanding, timely implementation will need considerable cajoling within each company. I am not being opportunistic or pessimistic but being realistic....
Pages: « Previous  28 29 30 31 32 33 34 35 36 [37] 38 39 40 41 42 43 44 45 46 Next »




RSS Follow us on Twitter Join us on LinkedIn Like us on Facebook Youtube channel
contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa